期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/jcm11113099
关键词
COVID-19; heparin; low molecular weight heparin; coagulopathy; thromboprophylaxis
COVID-19 is associated with an increased risk of VTE and coagulopathy, with endothelial damage being a crucial mechanism. Heparin has multiple biological actions in the treatment of COVID-19.
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism for the development of complications in an acute phase of the illness and for several postdischarge sequalae. Heparin has been shown to have a positive impact on COVID-19 due to its anticoagulant function. Moreover, several other biological actions of heparin were postulated: a potential anti-inflammatory and antiviral effect through the main protease (M-pro) and heparansulfate (HS) binding and a protection from the damage of vascular endothelial cells. In this paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据